Opendata, web and dolomites

SENATOR TERMINATED

Staff Exchange for Novel applications in 19f magnetic resonance imaging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SENATOR project word cloud

Explore the words cloud of the SENATOR project. It provides you a very rough idea of what is the project "SENATOR" about.

2015    quantitative    visualised    magnetic    incorporated    impairment    diagnostic    reagents    found    area    absolutely    opened    risk    insights    kidneys    nanoparticles    bone    patients    signatures    fda    surrounding    accumulate    spurred    functionalisation    generation    animals    payload    biology    agents    structures    gbca    move    labelled    materials    body    brain    gbcas    migration    safety    announcement    basis    mri    ligands    tissue    advised    deposits    technique    multifunctional    competing    smart    administered    cells    door    deemed    biomaterial    background    active    perfluorocarbon    resolution    inside    19f    living    therapeutic    situations    discrimination    trafficking    renal    generally    limit    historically    novelty    tolerated    accumulated    contrast    individual    mounting    signal    regarding    tissues    clinical    preclinical    modality    whilst    imaged    safe    resonance    gadolinium    molecular    imaging    healthcare    expansion    cell    repeated    invasive    released    until    professionals   

Project "SENATOR" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 1˙541˙000 €
 EC max contribution 1˙541˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 234˙600.00
2    PERCUROS BV NL (LEIDEN) participant 202˙400.00
3    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 165˙600.00
4    UNIVERSITA DEGLI STUDI DI CAMERINO IT (CAMERINO) participant 161˙000.00
5    TECOBIOSCIENCES GMBH DE (LANDSHUT) participant 156˙400.00
6    UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II IT (NAPOLI) participant 156˙400.00
7    MEDRES-MEDICAL RESEARCH GMBH DE (KOLN) participant 147˙200.00
8    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 110˙400.00
9    GOOD BIOMARKER SCIENCES BV NL (SASSENHEIM) participant 82˙800.00
10    PROGREDUM GMBH DE (KAISERSLAUTERN) participant 82˙800.00
11    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 41˙400.00

Map

 Project objective

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique, which is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration. For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue. The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality. Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently. However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENATOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENATOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

CONMECH (2019)

Nonsmooth Contact Dynamics

Read More  

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More  

ENDORSE (2018)

Safe, Efficient and Integrated Indoor Robotic Fleet for Logistic Applications in Healthcare and Commercial Spaces

Read More  
lastchecktime (2022-08-08 19:43:02) correctly updated